At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
SPARC1103 low dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of SPARC1103 in Subjects With Spasticity
In Brief
A Phase 2 clinical trial evaluating SPARC1103 low dose, SPARC1103 high dose, and 1 other intervention for Spasticity. Completed, enrolled 142 participants across 23 sites in 3 countries.
Detailed Summary
Study of SPARC1103 in subjects with spasticity
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpasticity
CountriesRussia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartApr 2014
Primary CompletionApr 2017
TodayJul 2026
First PostedJan 3, 2014
Enrollment StartApr 21, 2014
Primary CompletionApr 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.5 years ago
Interventions
SPARC1103 low dosedrug
once daily
SPARC1103 high dosedrug
once daily
SPARC Placebodrug